A Shabaik, G Lin, M Peterson… - Diagnostic …, 2011 - Wiley Online Library The prognostic and predictive value of Her2/neu and the hormone receptors in patient with primary or metastatic breast cancer is essential for a favorable outcome of treatment. We have been experiencing increasing requests to test cytologic specimens for these markers in patients with ... Related articles - All 2 versions
B Aktas, V Müller, M Tewes, J Zeitz… - Gynecologic …, 2011 - ncbi.nlm.nih.gov OBJECTIVES: The expression of predictive markers including the estrogen (ER) and progesterone receptor (PR) expression can change during the course of the disease. Therefore, reassessment of these markers at the time of disease progression might help to optimize treatment ...
TN Pathiraja, PB Shetty, J Jelinek, R He… - Clinical Cancer …, 2011 - AACR ...Progesteronereceptor isoform-specific promoter methylation - Updated Version 10.1158/1078-0432.CCR-10-2950 doi: Access the most recent version of this article at: ... Page 2. 1 Progesteronereceptor isoform-specific promoter methylation — Association of PRA promoter ... Related articles - All 2 versions
TN Pathiraja, PB Shetty, J Jelinek, R He… - Clinical Cancer …, 2011 - AACR Purpose: ERα and PR levels are critical determinants for breast cancer prognosis and response to endocrine therapy. Although PR is known to be silenced by methylation of its promoter, few studies have correlated methylation with PR levels and outcome in breast cancer. There ... Related articles
H Anderson, M Hills, L Zabaglo… - Annals of …, 2011 - Eur Soc Med Oncology Background: Surprisingly few data are published on the relevance of even commonly used biomarkers of response to aromatase inhibitors (AIs) in advanced breast cancer. Here, we aim to determine the effectiveness of AIs in that setting according to quantitative levels of estrogen receptor ... Cited by 1 - Related articles - All 2 versions